BRPI0909378A2 - métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b - Google Patents
métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2bInfo
- Publication number
- BRPI0909378A2 BRPI0909378A2 BRPI0909378A BRPI0909378A BRPI0909378A2 BR PI0909378 A2 BRPI0909378 A2 BR PI0909378A2 BR PI0909378 A BRPI0909378 A BR PI0909378A BR PI0909378 A BRPI0909378 A BR PI0909378A BR PI0909378 A2 BRPI0909378 A2 BR PI0909378A2
- Authority
- BR
- Brazil
- Prior art keywords
- antagonist
- methods
- treating disorders
- nr2b subtype
- selective nr2b
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4008708P | 2008-03-27 | 2008-03-27 | |
| PCT/EP2009/002241 WO2009118187A1 (en) | 2008-03-27 | 2009-03-26 | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0909378A2 true BRPI0909378A2 (pt) | 2015-10-06 |
Family
ID=40910288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0909378A BRPI0909378A2 (pt) | 2008-03-27 | 2009-03-26 | métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110053951A1 (enExample) |
| EP (1) | EP2254580A1 (enExample) |
| JP (3) | JP2011516417A (enExample) |
| KR (1) | KR20100135847A (enExample) |
| CN (1) | CN101977606A (enExample) |
| AU (1) | AU2009228660B2 (enExample) |
| BR (1) | BRPI0909378A2 (enExample) |
| CA (1) | CA2719749A1 (enExample) |
| IL (1) | IL207835A0 (enExample) |
| MX (1) | MX2010009649A (enExample) |
| NZ (1) | NZ588698A (enExample) |
| RU (1) | RU2499598C2 (enExample) |
| WO (1) | WO2009118187A1 (enExample) |
| ZA (1) | ZA201006587B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013251079B2 (en) | 2012-04-20 | 2017-03-23 | Ucb Pharma S.A. | Methods for treating Parkinson's disease |
| WO2015175806A1 (en) | 2014-05-16 | 2015-11-19 | The Trustees Of The University Of Pennsylvania | Applications of automatic anatomy recognition in medical tomographic imagery based on fuzzy anatomy models |
| JP6605020B2 (ja) | 2014-08-15 | 2019-11-13 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | Ｎｒ２ｂ受容体阻害剤としてのトリアゾール |
| HUE049278T2 (hu) | 2014-08-15 | 2020-09-28 | Janssen Pharmaceuticals Inc | Pirazolok |
| CN107849010B (zh) | 2015-06-01 | 2021-11-09 | 卢郡控股(开曼)有限公司 | 作为nr2b nmda受体拮抗剂的3,3‐二氟哌啶氨基甲酸酯杂环化合物 |
| SMT202000134T1 (it) | 2015-07-09 | 2020-05-08 | Janssen Pharmaceutica Nv | 4-azaindoli sostituiti e loro uso come modulatori del recettore glun2b |
| BR112018016329A2 (pt) | 2016-02-10 | 2018-12-18 | Janssen Pharmaceutica Nv | 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b |
| US10487055B2 (en) | 2016-06-01 | 2019-11-26 | Rhode Island Board Of Education | Diindole compounds useful in treatment of nervous system disorders |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| US10732235B2 (en) * | 2018-03-29 | 2020-08-04 | Siemens Healthcare Gmbh | Magnetic resonance method and apparatus using atlas-based masking for quantitative susceptibility mapping |
| JP7346441B2 (ja) | 2018-04-04 | 2023-09-19 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピリジン及びピリミジン並びにｇｌｕｎ２ｂ受容体調節物質としてのそれらの使用 |
| KR20220024403A (ko) | 2019-06-14 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도 |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| CA3142998A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as glun2b receptor modulators |
| BR112021025141A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b |
| US11618750B2 (en) | 2019-06-14 | 2023-04-04 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators |
| MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
| CA3143102A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199801774T2 (xx) * | 1996-03-08 | 1998-12-21 | F.Hoffmann-La Roche Ag | 4-fenil-3, 6-dihidro-2H- piridil t�revlerinin, NMDA resept�r alttip blokerleri olarak kullan�m�. |
| US5985936A (en) * | 1997-12-18 | 1999-11-16 | Forbes Medi-Tech, Inc. | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
| US6015824A (en) * | 1998-02-10 | 2000-01-18 | Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders |
| TWI254043B (en) * | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
| DK1070708T3 (da) * | 1999-07-21 | 2004-05-10 | Hoffmann La Roche | Triazolderivater |
| EP1278728B1 (en) * | 2000-04-20 | 2004-08-25 | F. Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders |
| US6432985B2 (en) * | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
| AU2001296994A1 (en) * | 2000-10-06 | 2002-04-15 | Regents Of The University Of California | Nmda receptor channel blocker with neuroprotective activity |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| EP1915624A1 (en) * | 2005-07-29 | 2008-04-30 | Regents of the University of Minnesota | Amyloid beta receptor and uses thereof |
-
2009
- 2009-03-26 BR BRPI0909378A patent/BRPI0909378A2/pt not_active IP Right Cessation
- 2009-03-26 KR KR1020107023896A patent/KR20100135847A/ko not_active Ceased
- 2009-03-26 NZ NZ588698A patent/NZ588698A/en not_active IP Right Cessation
- 2009-03-26 CN CN2009801104274A patent/CN101977606A/zh active Pending
- 2009-03-26 RU RU2010143864/15A patent/RU2499598C2/ru not_active IP Right Cessation
- 2009-03-26 MX MX2010009649A patent/MX2010009649A/es active IP Right Grant
- 2009-03-26 EP EP09724248A patent/EP2254580A1/en not_active Withdrawn
- 2009-03-26 CA CA2719749A patent/CA2719749A1/en not_active Abandoned
- 2009-03-26 WO PCT/EP2009/002241 patent/WO2009118187A1/en not_active Ceased
- 2009-03-26 JP JP2011501153A patent/JP2011516417A/ja active Pending
- 2009-03-26 AU AU2009228660A patent/AU2009228660B2/en not_active Ceased
- 2009-03-26 US US12/919,804 patent/US20110053951A1/en not_active Abandoned
-
2010
- 2010-08-26 IL IL207835A patent/IL207835A0/en unknown
- 2010-09-14 ZA ZA2010/06587A patent/ZA201006587B/en unknown
-
2014
- 2014-02-05 JP JP2014020051A patent/JP2014098018A/ja active Pending
-
2015
- 2015-12-03 JP JP2015236571A patent/JP2016094430A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011516417A (ja) | 2011-05-26 |
| WO2009118187A1 (en) | 2009-10-01 |
| MX2010009649A (es) | 2010-12-17 |
| ZA201006587B (en) | 2012-02-29 |
| CA2719749A1 (en) | 2009-10-01 |
| AU2009228660A1 (en) | 2009-10-01 |
| JP2016094430A (ja) | 2016-05-26 |
| NZ588698A (en) | 2012-06-29 |
| IL207835A0 (en) | 2010-12-30 |
| AU2009228660B2 (en) | 2012-11-29 |
| JP2014098018A (ja) | 2014-05-29 |
| RU2499598C2 (ru) | 2013-11-27 |
| US20110053951A1 (en) | 2011-03-03 |
| EP2254580A1 (en) | 2010-12-01 |
| KR20100135847A (ko) | 2010-12-27 |
| CN101977606A (zh) | 2011-02-16 |
| RU2010143864A (ru) | 2012-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0909378A2 (pt) | métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b | |
| CY2020036I1 (el) | Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p | |
| BR112012025101A2 (pt) | compostos antagonistas seletivos de receptor nk-3, composição farmacêutica e métodos para uso em distúrbios mediados por receptores nk-3 | |
| BRPI0912362A2 (pt) | antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos | |
| IL248652A0 (en) | Methods, compositions and devices for facilitating re-creation | |
| IL212986A0 (en) | Methods for treating eye disorders | |
| BRPI0816845A2 (pt) | Método aperfeiçoado para regeneração de absorvente | |
| IL232222A0 (en) | Methods for treating progressive multiple sclerosis | |
| BRPI0922046A2 (pt) | dispositivo de reprodução, método de reprodução e programa para reprodução estereoscópica | |
| HRP20170246T1 (hr) | Režim doziranja za selektivni agonist s1p1-receptora | |
| GB2467710B (en) | Methods for treating social disorders | |
| FI20085171L (fi) | Uudet selluloosajohdannaiset, menetelmä niiden valmistamiseksi sekä niiden käyttö | |
| BRPI0810071A2 (pt) | Método para determinação do risco inicial de glaucoma | |
| DK2244628T3 (da) | Patientdata-sensorapparat | |
| BRPI0914680A2 (pt) | método para produção de dispositivos de distribuição | |
| FI20085296L (fi) | Menetelmä kipsin puhdistamiseksi | |
| EP2331097A4 (en) | METHOD FOR TREATING CNS DISEASES | |
| BRPI0914393A2 (pt) | "método para caracterização de fitoquímicos" | |
| BRPI0820406A2 (pt) | Métodos para identificar aumento de antagonistas do receptor nmda | |
| EP2387402A4 (en) | METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS WITH 2,4-PYRIMIDINIAMIN COMPOUNDS | |
| ES2451508T8 (es) | Proceso de acervación múltiple simultánea | |
| BRPI0909659A2 (pt) | tratamento para distúrbios relacionados oculares | |
| BRPI0919599A2 (pt) | aparelho para jogar jogos de azar | |
| BRPI0919310A2 (pt) | aparelho para fazer medições em poços, e método para fazer medições em poços. | |
| BRPI1014007A2 (pt) | aparelho para seleção de suspensões de fibra. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: EVOTEC INTERNATIONAL GMBH (DE) |
|
| B25G | Requested change of headquarter approved |
Owner name: EVOTEC INTERNATIONAL GMBH (DE) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |